{
    "ticker": "RVPHW",
    "name": "Reviva Pharmaceuticals Holdings, Inc.",
    "description": "Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders and other unmet medical needs. Founded in 2011 and headquartered in the San Francisco Bay Area, Reviva is dedicated to addressing the challenges faced by patients suffering from conditions such as schizophrenia and Parkinson's disease. The company's lead product candidate, RP5063, is a novel antipsychotic designed to improve the treatment of schizophrenia while minimizing side effects associated with traditional therapies. Reviva's proprietary drug discovery platform utilizes advanced technologies to develop compounds that target specific receptors in the brain, aiming to enhance efficacy and safety. The company is also exploring additional indications for its pipeline candidates, including other CNS disorders and metabolic diseases. Committed to scientific excellence and patient-centric approaches, Reviva Pharmaceuticals is poised to make significant contributions to the field of psychiatry and neurology, leveraging its expertise in drug development and strategic partnerships to bring new options to patients in need.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2011",
    "website": "https://www.revivapharma.com",
    "ceo": "Lynn Kirkpatrick",
    "social_media": {
        "twitter": "https://twitter.com/revivapharma",
        "linkedin": "https://www.linkedin.com/company/reviva-pharmaceuticals/"
    },
    "investor_relations": "https://www.revivapharma.com/investor-relations",
    "key_executives": [
        {
            "name": "Lynn Kirkpatrick",
            "position": "CEO"
        },
        {
            "name": "D. Scott Kelly",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "CNS Disorders",
            "products": [
                "RP5063"
            ]
        }
    ],
    "seo": {
        "meta_title": "Reviva Pharmaceuticals Holdings, Inc. | Innovative CNS Therapies",
        "meta_description": "Explore Reviva Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing innovative therapies for CNS disorders. Learn about our lead product RP5063 and our commitment to addressing unmet medical needs.",
        "keywords": [
            "Reviva Pharmaceuticals",
            "CNS Disorders",
            "RP5063",
            "Biopharmaceuticals",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is Reviva Pharmaceuticals known for?",
            "answer": "Reviva Pharmaceuticals is known for developing innovative therapies for central nervous system disorders, particularly schizophrenia."
        },
        {
            "question": "Who is the CEO of Reviva Pharmaceuticals?",
            "answer": "Lynn Kirkpatrick is the CEO of Reviva Pharmaceuticals Holdings, Inc."
        },
        {
            "question": "Where is Reviva Pharmaceuticals headquartered?",
            "answer": "Reviva Pharmaceuticals is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are Reviva's main products?",
            "answer": "Reviva's main product candidate is RP5063, which is being developed for the treatment of schizophrenia."
        },
        {
            "question": "When was Reviva Pharmaceuticals founded?",
            "answer": "Reviva Pharmaceuticals was founded in 2011."
        }
    ],
    "competitors": [
        "JNJ",
        "PFE",
        "ABBV",
        "BIIB"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "NVDA",
        "MRNA"
    ]
}